These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 1884248)
1. The effect of tumor burden on ornithine decarboxylase activity in mice. Saydjari R; Alexander RW; Upp JR; Poston GJ; Barranco SC; Townsend CM; Thompson JC Cancer Invest; 1991; 9(4):415-9. PubMed ID: 1884248 [TBL] [Abstract][Full Text] [Related]
2. Systemic alterations in ornithine decarboxylase activity caused by colon cancer in mice. Saydjari R; Beauchamp RD; Townsend CM; Thompson JC Cancer Lett; 1991 Jun; 58(1-2):155-8. PubMed ID: 2049780 [TBL] [Abstract][Full Text] [Related]
3. Studies on the effects of an ornithine decarboxylase inhibitor on lupus nephritis reveal a post-transcriptional modification of the enzyme. Hsu HC; Thomas T; Seibold JR; Thomas TJ Agents Actions; 1993; 39 Spec No():C204-6. PubMed ID: 8273569 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine. Qu N; Ignatenko NA; Yamauchi P; Stringer DE; Levenson C; Shannon P; Perrin S; Gerner EW Biochem J; 2003 Oct; 375(Pt 2):465-70. PubMed ID: 12859253 [TBL] [Abstract][Full Text] [Related]
5. Influence of gastrin, gastrin receptor blockers, epidermal growth factor, and difluoromethylornithine on the growth and the activity of ornithine decarboxylase of colonic carcinoma cells. Eggstein S; Imdahl A; Kohler M; Waibel M; Farthmann EH J Cancer Res Clin Oncol; 1991; 117(1):37-42. PubMed ID: 1997467 [TBL] [Abstract][Full Text] [Related]
6. Eflornithine (DFMO) prevents progression of pancreatic cancer by modulating ornithine decarboxylase signaling. Mohammed A; Janakiram NB; Madka V; Ritchie RL; Brewer M; Biddick L; Patlolla JM; Sadeghi M; Lightfoot S; Steele VE; Rao CV Cancer Prev Res (Phila); 2014 Dec; 7(12):1198-209. PubMed ID: 25248858 [TBL] [Abstract][Full Text] [Related]
7. 2-Deoxy-D-glucose inhibits the antitumor effects of alpha-difluoromethylornithine on the growth of colon cancer in vivo. Saydjari R; Upp JR; Alexander RW; Barranco SC; Townsend CM; Thompson JC Invest New Drugs; 1989 Jul; 7(2-3):131-8. PubMed ID: 2507471 [TBL] [Abstract][Full Text] [Related]
8. Successful treatment of lupus nephritis in MRL-lpr/lpr mice by inhibiting ornithine decarboxylase. Gunnia UB; Amenta PS; Seibold JR; Thomas TJ Kidney Int; 1991 May; 39(5):882-90. PubMed ID: 2067204 [TBL] [Abstract][Full Text] [Related]
9. Differential sensitivity of various human tumors to inhibition of polyamine biosynthesis in vivo. Saydjari R; Alexander RW; Upp JR; Barranco SC; Townsend CM; Thompson JC Int J Cancer; 1991 Jan; 47(1):44-8. PubMed ID: 1985877 [TBL] [Abstract][Full Text] [Related]
10. Effects of gastrin and difluoromethylornithine on growth of human colon cancer. Smith JP; Kramer ST; Demers LM Dig Dis Sci; 1993 Mar; 38(3):520-8. PubMed ID: 8444085 [TBL] [Abstract][Full Text] [Related]
11. Apparent ornithine decarboxylase activity, measured by 14CO2 trapping, after frozen storage of rat tissue and rat tissue supernatants. Gaines DW; Friedman L; McCann PP Anal Biochem; 1988 Oct; 174(1):88-96. PubMed ID: 3146234 [TBL] [Abstract][Full Text] [Related]
12. Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells. Selamnia M; Mayeur C; Robert V; Blachier F Biochem Pharmacol; 1998 Apr; 55(8):1241-5. PubMed ID: 9719479 [TBL] [Abstract][Full Text] [Related]
14. Stable ornithine decarboxylase in a rat hepatoma cell line selected for resistance to alpha-difluoromethylornithine. Mitchell JL; Hoff JA; Bareyal-Leyser A Arch Biochem Biophys; 1991 Oct; 290(1):143-52. PubMed ID: 1898085 [TBL] [Abstract][Full Text] [Related]
15. Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. Love RR; Carbone PP; Verma AK; Gilmore D; Carey P; Tutsch KD; Pomplun M; Wilding G J Natl Cancer Inst; 1993 May; 85(9):732-7. PubMed ID: 8478959 [TBL] [Abstract][Full Text] [Related]